A Phase 1/2 Dose Escalation Study of AP-002 In Patients With Advanced or Recurrent Solid Tumors
Latest Information Update: 08 Oct 2021
At a glance
- Drugs AP-002 (Primary)
- Indications Advanced breast cancer; Bone metastases; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Altum Pharmaceuticals
Most Recent Events
- 04 Nov 2019 New trial record